Please login to the form below
Oesophageal cancer
This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
Latest news
-
Merck’s Keytruda gains two more approvals in Japan
The second indication is in colorectal cancer, targeting unresectable, advanced or recurrent high microsatellite instability (MSI-H) colorectal cancer. ... In the US alone, it is indicated for cancers including melanoma, non-small cell lung cancer,
-
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer
Merck &Co’s – known as MSD outside the US and Canada – Keytruda has received an approval from the US Food and Drug Administration (FDA) for the treatment of advanced oesophageal cancer. ... status. “There have been few advances in improving
-
BMS aims for US approval of Opdivo combo in stomach cancer
The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or oesophageal adenocarcinoma (EAC). ... free survival (PFS) in patients with
-
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation
such as stage III NSCLC and locally advanced oesophageal cancer. ... On top of these studies, tiragolumab is being evaluated in metastatic oesophageal squamous cancer and cervical cancer.
-
BMS’ Opdivo wins EU approval for second-line oesophageal cancer
The US Food and Drug Administration (FDA) has already approved Opdivo for second-line advanced oesophageal cancer treatment, giving the immunotherapy a green light in June. ... Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD)
More from news
Approximately 6 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Deal Watch March 2016
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
